<document id="DDI-DrugBank.d502">
    <sentence id="DDI-DrugBank.d502.s0" text="Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.">
        <entity charOffset="0-7" id="DDI-DrugBank.d502.s0.e0" text="Ocupress" type="brand" />
        <entity charOffset="69-98" id="DDI-DrugBank.d502.s0.e1" text="beta-adrenergic blocking agent" type="group" />
        <pair ddi="true" e1="DDI-DrugBank.d502.s0.e0" e2="DDI-DrugBank.d502.s0.e1" id="DDI-DrugBank.d502.s0.p0" type="advise" />
    </sentence>
    <sentence id="DDI-DrugBank.d502.s1" text="Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.">
        <entity charOffset="55-66" id="DDI-DrugBank.d502.s1.e0" text="beta-blocker" type="group" />
        <entity charOffset="144-152" id="DDI-DrugBank.d502.s1.e1" text="reserpine" type="drug" />
        <pair ddi="true" e1="DDI-DrugBank.d502.s1.e0" e2="DDI-DrugBank.d502.s1.e1" id="DDI-DrugBank.d502.s1.p0" type="advise" />
    </sentence>
</document>